Local VCs more worried about FDA moves than healthcare reform

VC logo

Concerns in the investment community over changes in the 510(k) clearance process and other uncertainty over new regulation at the Food & Drug Administration outweigh worries about the healthcare reform act, according to a MassDevice survey of local med-tech investors.

The survey, conducted with the help of the New England Venture Network, polled a dozen VC professionals in the life science community. The respondents said that, overall, the climate for medical technology investment was “mostly negative.” The survey was kept small and anonymous to ensure open and honest responses.

The investors cited regulatory changes at the Food & Drug Administration as their primary concern.

“For now, we have stopped investing in any new med-tech companies with FDA exposure,” wrote one investor.

Another pointed directly to the agency’s proposed changes as directly affecting the investment climate.

“Fear of further FDA regulation, including 510(k) reform, is making it very difficult to manage risk and leading to fewer investments in devices,” that investor wrote.

In fact, most investors said major changes to the 510(k) process would be the most damaging to deal flow, even more so than the 2.3 percent excise tax imposed on American medical device makers as part of healthcare reform. An exclusive new MassDevice report shows that 510(k) decision times increased once again in 2009, to an average of 119 days — up 37 percent from 2005, when times to decision averaged 87 days.

“Early-stage medical device investment has already slowed considerably due to regulatory issues. The incremental effect of the tax will be small compared to the damage already done,” wrote one investor.

But that doesn’t mean the device tax will have no effect on deal flow. Investors were very negative on the impact of the tax. Here’s a sampling of what they wrote:

  • “To put it in perspective, 2.3 percent of revenues is approximately equivalent to one-third to one-quarter, or the amount that the big med-tech companies spend on R&D annually. The money has to come from somewhere, and I doubt all will come from profits (at least I doubt that is what their shareholders will want).”
  • “Price pressure is already squeezing margins. This means we have to invest more money for less gain. It is bad for returns. Median returns to healthcare venture capital are already poor, and this will only make it worse. In the short term it will raise revenue. In the long run innovation will suffer.”
  • “Currently, time lags to reimbursement and increased development timelines have increase the time and money [required] to invest in medical device companies to reach profitability. An additional excise tax on the medical device industry enhances this problem, while also impacting the [proft and loss] of potential acquirers for any early-stage med tech company.”

The attitude toward healthcare reform generally was negative as well, with the investors saying that the bill doesn’t fix inherent problems in the system. One investor wrote that the bill “appears to have been a misguided effort at bringing the uninsured into a highly inefficient and dysfunctional system, instead of developing a better one for all.”

Overall, investors felt that the pharmaceutical and biotechnology industries emerged as winners in the healthcare reform act, while medical device companies, health insurers and the American public were its biggest losers.

Download MassDevice.com’s “Eye on the FDA” report for a detailed analysis of the increase in 510(k) decision times last year.

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply